CNCR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 23:00):
Our systems believe the stock currently is overvalued by -0.07% compare to its pairs and should correct downwards.

Stats
Šios dienos apimtis	9 129
Vidutinė apimtis	12 859
Rinkos kapitalizacija	16.52M
Last Dividend	$1.853 ( 2021-12-29 )
Next Dividend	$0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	$0.0480 (0.36%)

Koreliacija (AI algo v.1.1b): Overvalued: -0.07% $13.50 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Loncar Cancer Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
OZEM	1
AAIDX	0.935
BUJA	0.927
DFLI	0.927
NESRW	0.922
RENE	0.92
CPLSX	0.916
ATMV	0.914
BRKHW	0.909
AITR	0.905

10 Labiausiai neigiamai susiję koreliacijos
RDZN	-0.944
RENB	-0.942
ICUCW	-0.926
AIXI	-0.918
KITT	-0.91
ADNWW	-0.909
PTLO	-0.909
SHOT	-0.905
INDV	-0.905
CHNR	-0.905

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Financial Reports:

No articles found.

Loncar Cancer Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Loncar Cancer Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.106	2015-12-29
Last Dividend	$1.853	2021-12-29
Next Dividend	$0	N/A
Payout Date	2021-12-31
Next Payout Date	N/A
# dividends	4	--
Total Paid Out	$2.60	--
Avg. Dividend % Per Year	0.86%	--
Score	0.59	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2026-01-16)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.59

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2015	$0.106	0.42%
2016	$0	0.00%
2017	$0.350	1.62%
2018	$0	0.00%
2019	$0	0.00%
2020	$0.288	1.23%
2021	$1.853	5.87%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
29 Dec 2021	$1.853	28 Dec 2021	30 Dec 2021	31 Dec 2021
30 Dec 2020	$0.288	29 Dec 2020	31 Dec 2020	04 Jan 2021
28 Dec 2017	$0.350	28 Dec 2017	29 Dec 2017	02 Jan 2018
29 Dec 2015	$0.106	30 Nov -0001	31 Dec 2015	04 Jan 2016

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Diamond	2024-09-16	Monthly	14	15.03%	9.60
DMLP	Dividend Diamond	2024-04-26	Quarterly	22	10.71%	9.35
OXSQ	Dividend Diamond	2024-09-16	Monthly	21	12.73%	9.02
ARLP	Dividend Royal	2024-05-07	Quarterly	26	9.67%	8.87
PNNT	Dividend Royal	2024-06-14	Monthly	18	9.49%	8.82
MFIC	Dividend Royal	2024-06-11	Quarterly	21	10.89%	8.79
SPOK	Dividend Royal	2024-05-23	Quarterly	20	8.73%	8.72
PSEC	Dividend Royal	2024-06-25	Monthly	21	9.03%	8.65
SBLK	Dividend Royal	2024-06-06	Quarterly	17	13.10%	8.63
GBDC	Dividend Royal	2024-11-29	Bi-Monthly	15	8.53%	8.62

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	10.00	10.00	[0 - 0.3]
returnOnEquityTTM	0	1.500	10.00	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	0	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	0	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	0	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	10.00	10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	10.00	8.00	[0.5 - 2]
Total Score				0

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	0	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0	2.50	10.00	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	10.00	0	[0.1 - 0.5]
Total Score				0

Loncar Cancer Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Loncar Cancer

The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.